TABLE 2.
General anxiety disorder 7-item (GAD-7) scores of participants (N = 1,500).
| Variables | GAD-7 scores |
||||||||
| Means (SD) |
[95%CI] |
p
|
|||||||
| CN SH | CN Non-SH | NA and WE | CN SH | CN Non-SH | NA and WE | CN SH | CN Non-SH | NA and WE | |
| Gender | 0.578 | 0.731 | 0.664 | ||||||
| Male | 8.74 (3.97) | 5.23 (2.34) | 3.77 (1.80) | [8.27, 9.21] | [4.96, 5.50] | [3.54, 4.00] | |||
| Female | 9.11 (3.75) | 6.03 (2.08) | 4.11 (2.66) | [8.62, 9.60] | [5.75, 6.31] | [3.78, 4.44] | |||
| Vaccination status | 0.344 | 0.544 | 0.650 | ||||||
| 1 Dose | 8.69 (3.97) | 7.00 (3.33) | 4.21 (2.59) | [6.53, 10.85] | [4.93, 9.07] | [3.59, 4.83] | |||
| 2 Doses | 10.07 (4.81) | 5.70 (3.71) | 3.92 (2.57) | [8.29, 11.85] | [5.01, 6.39] | [3.43, 4.41] | |||
| 3 Doses | 8.98 (3.87) | 5.76 (3.56) | 3.89 (2.52) | [8.63, 9.33] | [5.40, 6.12] | [3.62, 4.16] | |||
| Infection status | 0.000 | 0.837 | 0.067 | ||||||
| Yes | 4.06 (2.65) | 10.50 (4.04) | 3.89 (2.48) | [2.67, 5.45] | [6.54, 14.46] | [3.64, 4.14] | |||
| No | 7.07 (4.11) | 5.73 (3.56) | 4.15 (2.74) | [6.70, 7.44] | [5.42, 6.04] | [3.63, 4.67] | |||
| VOC | 0.936 | 0.092 | 0.099 | ||||||
| SZAFS | 9.17 (3.86) | 5.63 (3.54) | 4.73 (3.07) | [8.62, 9.72] | [5.25, 6.01] | [3.77, 5.69] | |||
| SZAMM | 8.93 (3.93) | 7.16 (4.17) | 4.64 (2.29) | [8.13, 9.73] | [6.24, 8.08] | [3.64, 5.64] | |||
| SCV | 9.35 (3.31) | 6.05 (3.17) | 4.50 (2.87) | [8.89, 9.81] | [5.38, 6.72] | [4.23, 4.77] | |||
| PFTF | 0.823 | 0.526 | 0.284 | ||||||
| Yes | 9.13 (3.86) | 5.83 (3.54) | 3.29 (2.14) | [8.65, 9.61] | [5.38, 6.28] | [2.27, 4.31] | |||
| No | 8.94 (4.00) | 5.71 (3.64) | 3.96 (2.55) | [8.44, 9.44] | [5.27, 6.15] | [3.73, 4.19] | |||
| SATSO | 0.000 | 0.000 | 0.060 | ||||||
| No sequelae | 6.80 (5.36) | 3.64 (3.91) | 3.95 (2.50) | [2.11, 11.49] | [1.33, 5.95] | [3.66, 4.24] | |||
| Mild sequelae | 7.04 (3.93) | 4.64 (3.36) | 3.45 (2.69) | [5.99, 8.09] | [4.20, 5.08] | [2.94, 3.96] | |||
| Moderate sequelae | 7.17 (2.73) | 5.31 (2.34) | 4.42 (2.23) | [6.78, 7.56] | [4.93, 5.69] | [3.89, 4.95] | |||
| Severe sequelae | 10.85 (3.79) | 8.82 (3.61) | 4.34 (2.68) | [10.39, 11.31] | [8.16, 9.48] | [3.55, 5.13] | |||
CN, China, SH, Shanghai, NA, North America; WE, Western Europe; VOC, View of coexistence with COVID-19; SZAFS, Support zero-tolerance approach (because of fearing sequelae of Omicron); SZAMM, Support zero-tolerance approach (because of misgiving medical resource crowding); SCV, Support co-existence with virus as much as possible; PFTF, Psychological fear toward friends infected with COVID-19; SATSO, Subjective attitude toward the sequelae of Omicron.